ATE526977T1 - Verfahren zur inaktivierung infektioeser erreger in biologischen flüssigkeiten - Google Patents

Verfahren zur inaktivierung infektioeser erreger in biologischen flüssigkeiten

Info

Publication number
ATE526977T1
ATE526977T1 AT00988518T AT00988518T ATE526977T1 AT E526977 T1 ATE526977 T1 AT E526977T1 AT 00988518 T AT00988518 T AT 00988518T AT 00988518 T AT00988518 T AT 00988518T AT E526977 T1 ATE526977 T1 AT E526977T1
Authority
AT
Austria
Prior art keywords
plasma
animal
solvent system
inactivation
infectious pathogens
Prior art date
Application number
AT00988518T
Other languages
English (en)
Inventor
Bill Cham
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE526977T1 publication Critical patent/ATE526977T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT00988518T 1999-12-23 2000-12-28 Verfahren zur inaktivierung infektioeser erreger in biologischen flüssigkeiten ATE526977T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPQ4866A AUPQ486699A0 (en) 1999-12-23 1999-12-23 A method of treating infectious diseases
PCT/AU2000/001603 WO2001045718A1 (en) 1999-12-23 2000-12-28 A method of treating infectious diseases

Publications (1)

Publication Number Publication Date
ATE526977T1 true ATE526977T1 (de) 2011-10-15

Family

ID=3819005

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00988518T ATE526977T1 (de) 1999-12-23 2000-12-28 Verfahren zur inaktivierung infektioeser erreger in biologischen flüssigkeiten

Country Status (11)

Country Link
EP (1) EP1242099B1 (de)
JP (1) JP2003522740A (de)
KR (1) KR20020084079A (de)
AT (1) ATE526977T1 (de)
AU (2) AUPQ486699A0 (de)
BR (1) BR0016685A (de)
CA (1) CA2395125A1 (de)
ES (1) ES2372745T3 (de)
RU (1) RU2002119578A (de)
WO (1) WO2001045718A1 (de)
ZA (1) ZA200205327B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016246A2 (en) * 2003-06-20 2005-02-24 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
ES2715496T3 (es) 2003-07-03 2019-06-04 Hdl Therapeutics Inc Métodos y aparatos para crear derivados de partículas de HDL con un contenido reducido de lípidos
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US10821133B2 (en) 2017-12-28 2020-11-03 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
AU2018372198A1 (en) 2017-11-22 2020-06-11 Hdl Therapeutics, Inc. Systems and methods for priming fluid circuits of a plasma processing system

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1538322A (fr) * 1966-11-21 1968-09-06 Rhone Poulenc Sa Procédé de préparation d'une suspension virale inactivée
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4591505A (en) 1982-04-14 1986-05-27 New York Blood Center, Inc. Process for inactivating hepatitis B virus
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4895558A (en) 1985-07-15 1990-01-23 University Of Queensland Autologous plasma delipidation using a continuous flow system
ATE69383T1 (de) * 1985-11-22 1991-11-15 Schweiz Serum & Impfinst Verfahren zur herstellung eines tollwutimpfstoffes und nach diesem verfahren erhaltener impfstoff.
US5484396A (en) * 1988-11-17 1996-01-16 Naficy; Sadeque S. Method and device for treatment of HIV infections and AIDS
ES2224107T3 (es) 1993-07-30 2005-03-01 Aruba International Pty. Ltd. Sistema de deslipicacion de plasma.

Also Published As

Publication number Publication date
CA2395125A1 (en) 2001-06-28
AUPQ486699A0 (en) 2000-02-03
ZA200205327B (en) 2004-04-05
KR20020084079A (ko) 2002-11-04
BR0016685A (pt) 2003-02-25
ES2372745T3 (es) 2012-01-26
AU2493001A (en) 2001-07-03
EP1242099A1 (de) 2002-09-25
JP2003522740A (ja) 2003-07-29
AU783214B2 (en) 2005-10-06
EP1242099A4 (de) 2005-01-05
RU2002119578A (ru) 2004-01-27
WO2001045718A1 (en) 2001-06-28
EP1242099B1 (de) 2011-10-05

Similar Documents

Publication Publication Date Title
ATE191513T1 (de) Verfahren zur amplifikation von nukleinsäuren
ATE360363T1 (de) Verfahren und anordnung von beuteln zur konzentrierung weisser zellen
ATE325613T1 (de) Apherese von leukozyten aus blut zur behandlung von hiv
CO5300404A1 (es) Sistema y metodo para esterilizar un area de empaque de alimentos
DE3382723D1 (de) Adsorbens und Verfahren zu dessen Herstellung.
BR0212469A (pt) Método para multiplicação de vìrus em cultura de célula
DK0869776T3 (da) Stabiliserede nanopartikler, som kan filtreres under sterile betingelser
BRPI0416898A (pt) dispositivos de filtragem de fluxo tangencial e métodos para o enriquecimento de células-tronco
NO972608D0 (no) Opplösningshjelpemidler for hydrofile makromolekyler
MX9701183A (es) Procedimiento de preparacion del virus gripal, antigenos obtenidos y sus aplicaciones.
BRPI0417417A (pt) sistema de coleta de amostra de inibidor de fosfatase
WO2002067956A3 (en) Method for purifying a biological composition
ATE526977T1 (de) Verfahren zur inaktivierung infektioeser erreger in biologischen flüssigkeiten
CA3168772A1 (en) Storage container for cell-containing solution and storage solution
GB2441944A (en) Fieldbus system with shared redundancy system
CN112931487B (zh) 一种病毒保存液及其应用
DE602005019998D1 (de) Verfahren zur sterilisation von biologischen präparaten
Okado et al. Safety evaluation of nuclease P1 from Penicillium citrinum
ATE361068T1 (de) Wirkstoff zur entfernung einer unerwünschten proteinpopulation aus dem plasma
Pirnay et al. HIV transmission by transplantation of allograft skin: a review of the literature
SE0002287D0 (sv) Biotinderivat
WO2001077316A3 (en) Method of nucleic acid recovery
EP1356076A4 (de) Verfahren und zusammensetzungen zur extraktion von proteinen aus zellen
AU2284399A (en) Method for transforming plasma and implementing device
ES2170845T3 (es) Procedimiento para la inactivacion de virus en proteinas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties